BIOQUAL, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended November 30, 2016
January 26, 2017 at 08:53 pm IST
Share
BIOQUAL, Inc. reported unaudited earnings results for the second quarter and six months ended November 30, 2016. For the six months, the company reported revenue of $18,648,523 compared to $14,602,623 a year ago. Income before income taxes was $3,489,749 compared to $1,590,901 a year ago. Net income was $2,015,349 or $2.26 per diluted share compared to $918,601 or $1.03 per diluted share a year ago.
For the quarter, the company reported revenue of $9,482,331 compared to $8,004,826 a year ago. Income before income taxes was $1,759,360 compared to $1,196,119 a year ago. Net income was $1,016,160 or $1.14 per diluted share compared to $690,619 or $0.77 per diluted share a year ago.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.
BIOQUAL, INC. 
